We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
-13.68%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$179M
AUM Growth
-$34.5M
(-16%)
Cap. Flow
+$6.04M
Cap. Flow
% of AUM
3.37%
Top 10 Holdings %
Top 10 Hldgs %
60.25%
Holding
55
New
14
Increased
12
Reduced
10
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$4.1M |
| 2 |
Precision BioSciences
DTIL
|
+$4.01M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.67M |
| 4 |
United Therapeutics
UTHR
|
+$2.64M |
| 5 |
Rezolute
RZLT
|
+$2.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$5.52M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$3.96M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$2.47M |
| 4 |
GH Research
GHRS
|
+$2.29M |
| 5 |
LONA
LeonaBio Inc
LONA
|
+$1.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.88% |
| 2 | Financials | 7.74% |
| 3 | Miscellaneous | 3.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $25.1M | 13.96% |
554,000
| – | – |
|
|
WHWK
2
Whitehawk Therapeutics
WHWK
$233M
| $18.8M | 10.5% |
1,529,402
| – | – |
|
3
VistaGen Therapeutics
VTGN
$10.4M
| $10M | 5.57% |
378,715
-12,494
| -3% | -$441K |
|
4
Kura Oncology
KURA
$1.04B
| $9.83M | 5.48% |
536,500
+62,531
| +13% | +$899K |
|
|
BLSA
5
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.35M | 4.65% |
843,122
| – | – |
|
6
Xenon Pharmaceuticals
XENE
$5.55B
| $8.29M | 4.62% |
272,500
+47,500
| +21% | +$1.44M |
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $7.54M | 4.2% |
816,000
| – | – |
|
8
Celldex Therapeutics
CLDX
$3.06B
| $7.2M | 4.01% |
267,195
-55,703
| -17% | -$1.62M |
|
9
Relmada Therapeutics
RLMD
$448M
| $6.69M | 3.73% |
352,500
+10,500
| +3% | +$229K |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.34M | 3.53% |
94,500
+42,000
| +80% | +$2.67M |
|
|
JYAC
11
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.55M | 3.09% |
562,500
| – | – |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.42M | 3.02% |
563,607
+24,107
| +4% | +$303K |
|
|
13
Arcus Biosciences
RCUS
$3.25B
| $4.24M | 2.36% |
+167,500
| New | +$4.1M |
|
14
Syndax Pharmaceuticals
SNDX
$1.58B
| $3.94M | 2.2% |
205,003
-1,123
| -0.5% | -$18.7K |
|
15
Orchestra BioMed
OBIO
$347M
| $3.91M | 2.18% |
392,500
| – | – |
|
|
MRUS
16
DELISTED
Merus
MRUS
| $3.49M | 1.94% |
154,000
-81,500
| -35% | -$1.7M |
|
|
17
Precision BioSciences
DTIL
$184M
| $3.28M | 1.83% |
+68,345
| New | +$4.01M |
|
|
18
United Therapeutics
UTHR
$21.3B
| $3.06M | 1.71% |
+13,000
| New | +$2.64M |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.86M | 1.59% |
35,888
+2,688
| +8% | +$255K |
|
20
Milestone Pharmaceuticals
MIST
$114M
| $2.81M | 1.57% |
457,200
+77,200
| +20% | +$474K |
|
21
Viridian Therapeutics
VRDN
$2.48B
| $2.71M | 1.51% |
234,026
-105,974
| -31% | -$1.42M |
|
22
Aclaris Therapeutics
ACRS
$795M
| $2.69M | 1.5% |
192,835
-24,765
| -11% | -$347K |
|
|
23
GH Research
GHRS
$1.97B
| $2.43M | 1.35% |
243,250
-176,382
| -42% | -$2.29M |
|
24
EyePoint Inc
EYPT
$344M
| $2.39M | 1.33% |
303,396
-4,548
| -1% | -$45.7K |
|
25
Arrowhead Research
ARWR
$9.57B
| $2.18M | 1.21% |
61,926
-20,574
| -25% | -$774K |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Acuta Capital Partners held 55 positions worth $179M, down 16% from $214M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Acuta Capital Partners deployed $6.04M of net new capital in Q2 2022, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Arcus Biosciences: 167,500 shares worth $4.24M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was GH Research, an estimated $2.29M trimmed.
- Acuta Capital Partners's largest Q2 2022 buy was Arcus Biosciences: 167,500 shares worth $4.24M.
- Acuta Capital Partners added most to Mirati Therapeutics, Inc. Common Stock in Q2 2022, an estimated $2.67M increase.
- Acuta Capital Partners's biggest Q2 2022 reduction was GH Research, cutting an estimated $2.29M.
- Acuta Capital Partners fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $5.52M.
- Acuta Capital Partners's ten largest holdings make up 60% of its $179M portfolio in Q2 2022.
- Acuta Capital Partners opened 14 new positions and closed 12 in Q2 2022.
- Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $179M.
Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.